Jacob Chacko - 20 May 2021 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
President and CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
20 May 2021
Net transactions value
-$182,852
Form type
4
Filing time
24 May 2021, 19:27:50 UTC
Previous filing
19 May 2021
Next filing
28 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Sale $61,864 -2,468 -8.1% $25.07 27,934 20 May 2021 Direct F1, F2
transaction ORIC Common Stock Sale $120,688 -4,790 -17% $25.20 23,144 21 May 2021 Direct F1, F3
transaction ORIC Common Stock Sale $300 -12 -0.05% $25.00 23,132 24 May 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Represents the weighted average share price of an aggregate total of 2,468 shares sold in the price range of $25.00 to $25.14 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 4,790 shares sold in the price range of $25.00 to $25.37 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.